1. Home
  2. UEIC vs RNTX Comparison

UEIC vs RNTX Comparison

Compare UEIC & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Universal Electronics Inc.

UEIC

Universal Electronics Inc.

N/A

Current Price

$3.35

Market Cap

42.0M

ML Signal

N/A

RNTX

Rein Therapeutics Inc. Common Stock

BUY

Current Price

$1.48

Market Cap

38.9M

Sector

Health Care

ML Signal

BUY

Company Overview

Basic Information
Metric
UEIC
RNTX
Founded
1986
2001
Country
United States
United States
Employees
N/A
N/A
Industry
Consumer Electronics/Appliances
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
42.0M
38.9M
IPO Year
1993
N/A

Fundamental Metrics

Financial Performance
Metric
UEIC
RNTX
Price
$3.35
$1.48
Analyst Decision
Buy
Buy
Analyst Count
2
2
Target Price
$9.25
$10.00
AVG Volume (30 Days)
118.4K
212.7K
Earning Date
11-06-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$390,997,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
2.35
N/A
52 Week Low
$2.69
$1.04
52 Week High
$12.12
$3.50

Technical Indicators

Market Signals
Indicator
UEIC
RNTX
Relative Strength Index (RSI) 49.06 52.79
Support Level $3.06 $1.34
Resistance Level $3.36 $1.58
Average True Range (ATR) 0.18 0.11
MACD 0.06 -0.00
Stochastic Oscillator 85.38 57.14

Price Performance

Historical Comparison
UEIC
RNTX

About UEIC Universal Electronics Inc.

Universal Electronics Inc is a United States-based company that principally designs, develops, manufactures, ships, and supports control and sensor technology solutions and a broad line of universal control systems, audio-video (AV) accessories, wireless security, and smart home products that are used by the world's brands in the video services, consumer electronics, security, home automation, climate control and home appliance markets. It generates its total revenue from the United States.

About RNTX Rein Therapeutics Inc. Common Stock

Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.

Share on Social Networks: